Background Bacterial infections are a major cause of morbidity and mortality in patients who
are neutropenic following chemotherapy for malignancy. Trials have shown the efficacy of …

Antibiotics have been the most important risk factor for Clostridium difficile infection (CDI).
However, only data from non-randomised studies have been reviewed. We sought to …

This document updates and expands the initial Infectious Diseases Society of America
(IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in …

Owing to increasing resistance and the limited arsenal of new antibiotics, especially against
Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile …

Background Continuation of empirical antimicrobial therapy (EAT) for febrile neutropenia in
patients with haematological malignancies until neutrophil recovery could prolong the …

Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-
positive and Gram-negative bacteria. We did a systematic review of randomised trials that …

Imipenem, the first carbapenem discovered, was developed more than two decades ago in
response to an unmet need for a highly potent, broad-spectrum antimicrobial agent with a …

Objectives: Early, empirical broad-spectrum antibiotic treatment is the established practice
for febrile neutropenia. Several β-lactams are accepted for monotherapy. We asked whether …

Introduction: Immediate empirical antibiotic therapy is mandatory in febrile chemotherapy-
induced neutropenia, but its optimal duration is unclear, especially in patients with fever of …

Objectives Reducing antibiotic consumption has now become a major public health priority.
Reducing treatment duration is one of the means to achieve this objective. Guidelines on the …